Sarepta Therapeutics (SRPT) EBT (2016 - 2025)
Historic EBT for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $153.6 million.
- Sarepta Therapeutics' EBT rose 103160.49% to $153.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $373.0 million, marking a year-over-year increase of 49940.86%. This contributed to the annual value of $260.8 million for FY2024, which is 15013.94% up from last year.
- Per Sarepta Therapeutics' latest filing, its EBT stood at $153.6 million for Q2 2025, which was up 103160.49% from $171.7 million recorded in Q4 2024.
- Sarepta Therapeutics' 5-year EBT high stood at $171.7 million for Q4 2024, and its period low was -$512.7 million during Q1 2023.
- In the last 5 years, Sarepta Therapeutics' EBT had a median value of -$47.9 million in 2021 and averaged -$71.4 million.
- In the last 5 years, Sarepta Therapeutics' EBT plummeted by 86330.21% in 2021 and then soared by 103160.49% in 2025.
- Over the past 5 years, Sarepta Therapeutics' EBT (Quarter) stood at -$121.9 million in 2021, then increased by 16.89% to -$101.3 million in 2022, then surged by 139.85% to $40.4 million in 2023, then skyrocketed by 325.41% to $171.7 million in 2024, then fell by 10.54% to $153.6 million in 2025.
- Its last three reported values are $153.6 million in Q2 2025, $171.7 million for Q4 2024, and $34.0 million during Q3 2024.